Vera Hirsh
Impact in
- Pulmonary and Respiratory Medicine top 0.02%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Oncology top 0.05%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Bone health and treatments
- HER2/EGFR in Cancer Research
Papers in
-
- Lung Cancer Treatments and Mutations 110
- Lung Cancer Diagnosis and Treatment 15
- Oncology 89
- Lung Cancer Research Studies 36
- Bone health and treatments 20
- HER2/EGFR in Cancer Research 18
- Colorectal Cancer Treatments and Studies 18
- Co-authors
- Frances Alice Shepherd (12 shared papers)Tony S.K. Mok (37 shared papers)James Chih‐Hsin Yang (30 shared papers)Eng Huat Tan (3 shared papers)Sumitra Thongprasert (2 shared papers)Lesley Seymour (5 shared papers)Andrea Bezjak (3 shared papers)Michael Smylie (3 shared papers)
- Journals
- Annals of Oncology (26 papers)Journal of Thoracic Oncology (23 papers)Journal of Clinical Oncology (17 papers)Clinical Lung Cancer (13 papers)Lung Cancer (10 papers)
- Partner nations
- CanadaUnited StatesUnited Kingdom
In The Last Decade
Vera Hirsh
163 papers receiving 25.8k citations
Vera Hirsh's Hit Papers
Peers
Comparison fields: 5 of 133
- Pulmonary and Respiratory Medicine 16.7k
- Oncology 13.5k
- Cancer Research 3.2k
- Molecular Biology 5.3k
- Hepatology 462
Countries citing papers authored by Vera Hirsh
This map shows the geographic impact of Vera Hirsh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vera Hirsh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vera Hirsh more than expected).
Fields of papers citing papers by Vera Hirsh
This network shows the impact of papers produced by Vera Hirsh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vera Hirsh. The network helps show where Vera Hirsh may publish in the future.
Co-authors
The 25 scholars most cited alongside Vera Hirsh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 165 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Erlotinib in Previously Treated Non–Small-Cell Lung Cancer Hit paper breakdown → | 2005 | 4621 |
| 2 | Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer Hit paper breakdown → | 2013 | 2900 |
| 3 | Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Hit paper breakdown → | 2013 | 2751 |
| 4 | Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials Hit paper breakdown → | 2015 | 1348 |
| 5 | Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL Hit paper breakdown → | 2009 | 1246 |
| 6 | Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Hit paper breakdown → | 2008 | 1075 |
| 7 | Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial Hit paper breakdown → | 2016 | 991 |
| 8 | Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma Hit paper breakdown → | 2011 | 973 |
| 9 | Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial Hit paper breakdown → | 2012 | 839 |
| 10 | Weekly nab -Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial Hit paper breakdown → | 2012 | 650 |
| 11 | 2003 | 609 | |
| 12 | 2004 | 555 | |
| 13 | Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) Hit paper breakdown → | 2010 | 529 |
| 14 | Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial Hit paper breakdown → | 2017 | 439 |
| 15 | 2009 | 432 | |
| 16 | Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis Hit paper breakdown → | 2013 | 426 |
| 17 | 2003 | 330 | |
| 18 | 2016 | 296 | |
| 19 | 2012 | 286 | |
| 20 | 2013 | 266 |
About Vera Hirsh
Vera Hirsh is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Radiology, Nuclear Medicine and Imaging, Molecular Biology and Immunology, having authored 165 papers that have together received 26.7k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (110 papers), Lung Cancer Research Studies (36 papers), Bone health and treatments (20 papers), HER2/EGFR in Cancer Research (18 papers), Colorectal Cancer Treatments and Studies (18 papers), Lung Cancer Diagnosis and Treatment (15 papers), Cancer therapeutics and mechanisms (14 papers) and Radiopharmaceutical Chemistry and Applications (9 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (16.7k citations), Oncology (13.5k citations), Cancer Research (3.2k citations), Molecular Biology (5.3k citations) and Hepatology (462 citations). Vera Hirsh has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Frances Alice Shepherd, Tony S.K. Mok, James Chih‐Hsin Yang, Eng Huat Tan, Sumitra Thongprasert, Lesley Seymour, Andrea Bezjak, Michael Smylie, Tudor–Eliade Ciuleanu and José Rodrigues Pereira. Their work appears in journals such as Annals of Oncology, Journal of Thoracic Oncology, Journal of Clinical Oncology, Clinical Lung Cancer and Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.